RenovoRx (RNXT) Q3 2026 earnings review
RenovoRx catheter sales pass $1 million, but warrant exercises fund losses
RenovoRx, a medical-device maker selling a catheter that delivers chemotherapy directly to tumors, passed $1 million in quarterly sales while its cash burn stayed high. Third-quarter revenue rose 17% from last quarter to $1.1 million as active hospital customers grew from 21 to 26. Chief executive Shaun Bagai kept the full-year outlook unchanged, which by our math requires sales to jump 37% in the fourth quarter.
| Revenue | $1.07M +17% from last quarter (+301% from a year ago) |
|---|---|
| Active cancer centers | 26 up from 21 last quarter (year-end target: 36) |
| Cash burn before financing | $2.6M by our math; $10.4M cash left after $3.5M warrant inflow |
| Full-year revenue outlook | Unchanged $3.75M to $4.25M (implies $1.46M in Q4 at the middle) |
⚖️ Verdict: ⚪ Neutral
The story is unchanged because steady hospital additions were offset by slow clinical-site conversions and continued share dilution. Only one hospital from the newly completed Phase III pancreatic cancer trial converted to commercial orders during the quarter, leaving 10 hospital activations needed in the fourth quarter to hit the year-end goal of 36. Meanwhile, cash rose to $10.4 million only because investors exercised $3.5 million of warrants, lifting the share count 32% from a year ago without extending the company's cash runway past the second half of 2027.
The question now is whether converted clinical-trial hospitals will drive a fourth-quarter sales jump or merely shift clinical supplies into reported revenue. If trial hospitals order for a wider pool of commercial patients, fourth-quarter sales should reach the $1.5 million implied by the full-year plan; if approvals drag, both hospital additions and revenue will fall short. Fourth-quarter active hospital counts and research expenses will settle it.
🐂 Bull Case
Six Reps Drove Record Catheter Sales
RenovoRx sells RenovoCath, a specialized catheter that threads into an artery to bathe a tumor in chemotherapy. Chief executive Shaun Bagai said last quarter that third-quarter sales would beat the second quarter's record. "Our focused and regionally deployed sales team is sufficiently sized to address the market and effectively penetrate cancer centers that treat solid tumors, such as pancreatic cancer," Bagai said.
The medical-device maker delivered on that promise with a six-person sales group — one vice president and five regional managers. Third-quarter revenue rose 17% from last quarter to $1.07 million, and roughly quadrupled from a year ago, when adoption had briefly stalled.
- Active cancer centers: 26, up from 21 last quarter and 8 at the end of 2025
- Total sales funnel: more than 65 hospitals, up from 63 last quarter
- Revenue per average active center: about $45,000 by our math, compared with $49,000 last quarter
- Selling, general and administrative costs: $2.87 million, down slightly from $2.92 million last quarter
The numbers back Bagai's claim that the current team can open new hospital accounts without another jump in overhead. Revenue grew faster than commercial costs from last quarter, and most active hospitals placed repeat orders. Because average revenue per hospital dipped slightly as new sites joined, hitting the full-year target still requires faster hospital additions in the fourth quarter.
What to watch: fourth-quarter revenue per average active center. A reading near $45,000 would confirm that newly added hospitals order catheters at the same pace as early adopters.
Doctors Used the Catheter Beyond Late-Stage Pancreatic Cancer
RenovoRx built its business around Trans-Arterial Micro-Perfusion (TAMP), its method of pushing chemotherapy across an arterial wall into locally advanced pancreatic tumors that surgeons cannot remove. To outgrow that single niche, the life-sciences company needs physicians to use the catheter in earlier stages of pancreatic cancer and in other solid tumors.
In August an existing hospital customer performed the "first commercial clinical use in a solid tumor beyond pancreatic cancer", treating a patient with sarcoma, a cancer of the bone or soft tissue. In October researchers at the University of Vermont treated the first of roughly 10 planned patients in a study using the catheter before surgery, while two peer-reviewed journals published supporting data and RenovoRx finished enrolling its Phase III trial.
These steps matter because independent physicians are testing new uses through hospital-run studies that cost the California company very little. Treating patients before surgery or for sarcoma expands the pool of eligible procedures at hospitals that already stock the device.
What to watch: repeat sarcoma orders or enrollments in the bile-duct cancer study over the next two quarters. Steady procedure counts outside late-stage pancreatic cancer would show that theAugust sarcoma case was more than a one-off experiment.
🐻 Bear Case
Warrant Exercises Funded Operations as Share Count Grew
RenovoRx says its $10.4 million cash balance will fund the business "into the second half of 2027", when it expects initial results from its Phase III trial. Last quarter the company also outlined an internal plan to reach cash-flow break-even by the fourth quarter of 2027 at $5 million in quarterly sales, a target it did not repeat in this release.
Cash rose by $0.9 million during the third quarter only because investors paid $3.5 million from the "exercise of outstanding common stock warrants", which are options to buy new shares. Excluding that cash inflow, the business burned about $2.6 million in the quarter by our math.
- Operating loss: $3.24 million, unchanged from a year ago as commercial hiring offset lower trial costs
- Selling, general and administrative costs: 270% of revenue, down from 650% a year ago by our math
- Weighted-average shares: 48.2 million, up 31.5% from 36.6 million a year ago
- Implied cash burn before financing: $2.58 million in the third quarter, vs $2.88 million in the second quarter by our math
That math cuts against the idea that commercial growth is close to paying the bills. Even after collecting $3.5 million from warrant holders, the company did not extend its runway window past the second half of 2027, and four quarters of burn at the current pace would consume the entire $10.4 million cash pile before break-even.
What to watch: fourth-quarter cash burn excluding warrant or share sales. A burn number above $2.5 million would leave fewer than four quarters of cash entering 2027.
Only One Trial Site Converted to Commercial Use
Hospitals participating in the Phase III TIGeR-PaC trial — a study comparing catheter-delivered gemcitabine chemotherapy against intravenous chemotherapy — could not buy RenovoCath for routine commercial patients until trial enrollment finished in August. RenovoRx aims to convert up to 15 of those trial hospitals into paying customers during the second half of 2026 to help reach 36 active centers by year-end.
During the third quarter, the device maker recorded the "conversion of three devices from one clinical site in the TIGeR-PaC trial to a commercial cancer center customer at no gross margin". That accounting transfer lowered the quarterly gross margin to 82.4% from 84.3% in the second quarter, and left the company needing 10 more active hospitals in the fourth quarter — double the five it added in the third.
What to watch: the number of converted trial hospitals disclosed in the fourth-quarter report. Falling short of 10 total fourth-quarter additions would show that hospital purchasing committees take longer than two quarters to approve commercial orders after a trial ends.
Risks This Quarter Didn't Answer
Five standing risks received no new data in the third-quarter earnings release and await either the quarterly filing or next year's clinical readout.
- Customer concentration: three hospitals accounted for 52% of second-quarter sales; the third-quarter concentration footnote arrives in the Form 10-Q filing.
- Single supplier: Medical Murray manufactures the catheter under minimum purchase commitments; the quarterly filing will show remaining commitment balances.
- Phase III survival readout: topline overall survival data from the TIGeR-PaC study remains due in the second half of 2027.
- Competing systemic drugs: the company argues its catheter can deliver drugs alongside newer pills or injections, a claim that remains untested in clinical trials.
- Exchange listing rules: maintaining the Nasdaq listing remains a standard risk factor until share prices and equity stay comfortably above minimum thresholds.
💲 Other KPIs
Uncollected customer bills rose 26.9% from last quarter, outpacing the 17.3% rise in revenue, and More than quadrupled from $139 thousand at the end of 2025. Accounts receivable is money hospitals owe for delivered catheters, so a faster rise means more of the quarter's record sales had not yet turned into cash by September 30.
Research spending fell 26.4% from a year ago and edged up 3.4% from last quarter's $1.20 million. As the Phase III pancreatic cancer trial finished enrolling patients in August, clinical trial costs stayed near $1.2 million for a third straight quarter, down from roughly $1.7 million a quarter in 2025.
Catheter stock on hand dipped 11.0% from $383 thousand at the end of June, after doubling in the first quarter from $189 thousand at the end of 2025. Drawing down existing stock reduced cash tied up in working capital during the third quarter.
🔮 Guidance
Unchanged. The plan calls for full-year sales to more than triple from $1.12 million in 2025, up 256% at the middle of the range by our math. With $2.54 million booked through September, the middle of the range leaves $1.46 million for the fourth quarter — a 37% jump from the third quarter and more than six times the depressed fourth quarter of 2025.
Unchanged. RenovoRx still plans to finish 2026 with 36 active hospital customers, up from 8 at the end of 2025. Reaching that mark from 26 at the end of September requires activating 10 hospitals in the fourth quarter by our math, compared with 5 added in the third quarter and 5 in the second.
❓ Key Questions
How many Phase III trial hospitals have become paying customers?
Only one clinical trial site converted in the third quarter out of 15 the company previously expected in the second half. Hitting the year-end goal of 36 active centers depends on how many of the remaining 14 switch in the fourth quarter.
Did top-three customer concentration fall below half of sales?
Three hospitals generated 52% of revenue in the second quarter. The press release omits the major-customer breakdown, which is needed to tell whether the 10 hospitals added since March are broadening the revenue base or ordering only small trial batches.
Have all 114 Phase III patients completed randomization?
The release states that the TIGeR-PaC trial achieved full enrollment in August, but last quarter chief executive Shaun Bagai distinguished enrollment closure from final randomization of the 114th patient. The final randomized count sets the clock for the 86th survival event.
Does management still target cash break-even by late 2027?
Last quarter the finance chief outlined an internal plan to break even in the fourth quarter of 2027 at $5 million in quarterly sales. This release did not mention that target, and cash runway still stops in the second half of 2027.